Kendall Law Group Investigates Allos Therapeutics, Inc.

Kendall Law Group, led by former federal judge Joe Kendall, is investigating Allos Therapeutics, Inc. (NASDAQ: ALTH) for shareholders in connection with the proposed acquisition by AMAG Pharmaceuticals, Inc. The national securities firm’s investigation seeks to determine whether Allos Therapeutics and its Board breached their fiduciary duties by entering into the agreement without properly shopping for a deal that would provide better value for shareholders. If you are an Allos Therapeutics shareholder and would like additional information about your rights, contact the Kendall Law Group at 877-744-3728 or by email at investor@kendalllawgroup.com.

On July 20, 2011, the companies announced the definitive merger agreement under which Allos Therapeutics would be acquired by AMAG Pharmaceuticals, in a transaction valued at approximately $260 million. Under the terms of the agreement, Allos Therapeutics stockholders will receive a fixed ratio of 0.1282 shares of AMAG common stock for each share of Allos Therapeutics/ALTH common stock held. The deal values Allos Therapeutics stock at $2.44 a share using AMAG Pharmaceuticals' Tuesday closing price of $19.07. According to Thompson/First Call, analysts have set a price target as high as $8.00 per share for Allos Therapeutics’ stock. The firm’s investigation seeks to determine whether Allos Therapeutics and its Board undertook a fair process in negotiating the deal.

Kendall Law Group was founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in complex securities litigation. The firm has been counsel in numerous merger and acquisition cases nationwide, including some of the largest transactions in the United States.

Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From May 2024 to Jun 2024